Xi Yan

803 total citations · 1 hit paper
35 papers, 349 citations indexed

About

Xi Yan is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Xi Yan has authored 35 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 15 papers in Cancer Research and 11 papers in Molecular Biology. Recurrent topics in Xi Yan's work include HER2/EGFR in Cancer Research (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Angiogenesis and VEGF in Cancer (8 papers). Xi Yan is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Angiogenesis and VEGF in Cancer (8 papers). Xi Yan collaborates with scholars based in China, United States and Hong Kong. Xi Yan's co-authors include Feng Luo, Ming Jiang, Liqun Zou, Yu Jiang, Mei Li, Yanyang Liu, Tao Ning, Xia Wang, Zhixi Li and Jiaqi Han and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Xi Yan

27 papers receiving 346 citations

Hit Papers

Sacituzumab tirumotecan in previously treated metastatic ... 2025 2026 2025 5 10 15
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
    2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Peers

Xi Yan
Shun‐Chun Yang Taiwan
C-C. Lin Taiwan
Sima Torabian United States
B. Aika Shoo United States
Naoko Sakaguchi Japan
Kirsten Jost Germany
Rosanna Upstill‐Goddard United Kingdom
Georgia Kontostathi Greece
Isabel Matozzo United States
Joana Carvalho United Kingdom
Shun‐Chun Yang Taiwan
Xi Yan
Citations per year, relative to Xi Yan Xi Yan (= 1×) peers Shun‐Chun Yang

Countries citing papers authored by Xi Yan

Since Specialization
Citations

This map shows the geographic impact of Xi Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xi Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xi Yan more than expected).

Fields of papers citing papers by Xi Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xi Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xi Yan. The network helps show where Xi Yan may publish in the future.

Co-authorship network of co-authors of Xi Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Xi Yan. A scholar is included among the top collaborators of Xi Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xi Yan. Xi Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yin, Yongmei, Ying Fan, Xiaojia Wang, et al.. (2025). Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nature Medicine. 31(6). 1969–1975. 16 indexed citations breakdown →
2.
3.
4.
Huang, Jiayan, Cuicui Chang, Rui Li, et al.. (2025). Epigenetic regulatory mechanisms of autoimmune skin diseases: novel biomarkers and therapeutic prospects. Clinical Epigenetics. 17(1). 182–182.
5.
Cao, Xueshan, Xiaoxiao Tang, Yongdong Zou, et al.. (2024). Investigating metabolic dysregulation in serum of triple transgenic Alzheimer’s disease male mice: implications for pathogenesis and potential biomarkers. Amino Acids. 56(1). 10–10. 4 indexed citations
6.
Shu, Xin, et al.. (2024). MRAU-net: Multi-scale residual attention U-shaped network for medical image segmentation. Computers & Electrical Engineering. 118. 109479–109479. 8 indexed citations
7.
Wu, Lihong, Xiang-Xu Wang, Yan Wang, et al.. (2023). Construction and validation of a prognosis signature based on the immune microenvironment in gastric cancer. Frontiers in Surgery. 10. 1088292–1088292.
8.
Luo, Lu, Yuxin Yang, Xi Yan, et al.. (2023). Decrease in peripheral natural killer cell level during early pregnancy predicts live birth among women with unexplained recurrent pregnancy loss: a prospective cohort study. American Journal of Obstetrics and Gynecology. 230(6). 675.e1–675.e13. 8 indexed citations
9.
10.
Yang, Jianping, et al.. (2022). Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Frontiers in Pharmacology. 13. 924126–924126. 21 indexed citations
11.
Zhong, Xiaorong, Ting Luo, Zhongzheng Xiang, et al.. (2021). The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype. Annals of Surgical Oncology. 28(9). 5084–5095. 2 indexed citations
12.
13.
Luo, Ting, Xiaorong Zhong, Ping He, et al.. (2020). 225P Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer. Annals of Oncology. 31. S331–S331. 3 indexed citations
14.
Wang, Xia, Xi Yan, Dan Cao, et al.. (2015). Endostatin improves cancer-associated systemic syndrome in a lung cancer model. Oncology Letters. 9(5). 2023–2030. 1 indexed citations
15.
Luo, Ting, Ping He, Xiaorong Zhong, et al.. (2014). Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China. Pathology & Oncology Research. 21(2). 367–378. 5 indexed citations
16.
17.
Qiu, Meng, et al.. (2012). The role of palliative chemotherapy for terminally ill patients with advanced NSCLC. Thoracic Cancer. 4(2). 153–160. 7 indexed citations
18.
Peng, Qian, Mei Li, Ming Jiang, et al.. (2012). Polarization of tumor‐associated macrophage is associated with tumor vascular normalization by endostatin. Thoracic Cancer. 4(3). 295–305. 13 indexed citations
19.
Yan, Xi. (2010). Statistical Significance Testing:Problems and Reflection.
20.
Yan, Xi, Mei Li, Ming Jiang, et al.. (2009). Clinical characteristics of 45 patients with invasive pulmonary aspergillosis. Cancer. 115(21). 5018–5025. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shun‐Chun Yang Breakdown of academic impact, for papers by C-C. Lin Breakdown of academic impact, for papers by Sima Torabian Breakdown of academic impact, for papers by B. Aika Shoo Breakdown of academic impact, for papers by Naoko Sakaguchi Breakdown of academic impact, for papers by Kirsten Jost Breakdown of academic impact, for papers by Rosanna Upstill‐Goddard Breakdown of academic impact, for papers by Georgia Kontostathi Breakdown of academic impact, for papers by Isabel Matozzo Breakdown of academic impact, for papers by Joana Carvalho
Rankless by CCL
2026